Zobrazeno 1 - 10
of 169
pro vyhledávání: '"R T, O'Donnell"'
Publikováno v:
Cancer chemotherapy and biological response modifiers. 19
This promises to be an era of remarkable change for patients afflicted with NHL. Although the cause of NHL remains unknown, there is greater understanding of 'these diseases' at the molecular level. Insights into genetic aberrations that interrupt ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85542b92f1e787474a20b63672c17395
https://pubmed.ncbi.nlm.nih.gov/11686019
https://pubmed.ncbi.nlm.nih.gov/11686019
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 42(9)
Radiometal-labeled monoclonal antibodies are retained longer in tumors than iodinated antibodies, leading to their increased use for radioimmunotherapy. Dissociation of radioiodine from the antibody during metabolism has been documented. We now repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed51aae3c56bcfe22dc31eb8b0d66d56
https://pubmed.ncbi.nlm.nih.gov/11535720
https://pubmed.ncbi.nlm.nih.gov/11535720
Autor:
R T, O'Donnell, S J, DeNardo, A, Yuan, S, Shen, C M, Richman, P N, Lara, I J, Griffith, D S, Goldstein, D L, Kukis, G S, Martinez, G R, Mirick, G L, DeNardo, F J, Meyers
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(6)
Over 31,000 Americans die of androgen-independent metastatic prostate cancer each year. New strategies that do not involve hormonal manipulation but instead recognize the biochemical and molecular characteristics of prostate cancer are needed. Radioi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::09e1858d925ddb63661ad2c2b73ea82a
https://pubmed.ncbi.nlm.nih.gov/11410491
https://pubmed.ncbi.nlm.nih.gov/11410491
Publikováno v:
The Prostate. 44(3)
Radioimmunotherapy (RIT) is a new therapeutic modality capable of systemic delivery of radionuclides specifically to sites of metastatic cancer. The L6 monoclonal antibody has been shown to target prostate cancer in preclinical studies and, along wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0ed26841ec0f4bcc00c35e36e852d5c5
https://pubmed.ncbi.nlm.nih.gov/10906734
https://pubmed.ncbi.nlm.nih.gov/10906734
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 13(4)
The use of monoclonal antibodies (MoAbs) for immunotherapy and radioimmunotherapy has ushered in a new era in the treatment of non-Hodgkin's lymphoma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b523df25c6af837afcb437bf4f8a66c
https://pubmed.ncbi.nlm.nih.gov/10850358
https://pubmed.ncbi.nlm.nih.gov/10850358
Autor:
G L, DeNardo, R T, O'Donnell, S, Shen, L A, Kroger, A, Yuan, C F, Meares, D L, Kukis, S J, DeNardo
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(5)
Several monoclonal antibodies, including Lym-1, have proven effective for treatment of hematologic malignancies. Lym-1, which preferentially targets malignant lymphocytes, has induced therapeutic responses and prolonged survival in patients with non-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cef01ac4bc4a2091141af2b93c3b0e23
https://pubmed.ncbi.nlm.nih.gov/10809213
https://pubmed.ncbi.nlm.nih.gov/10809213
Autor:
R T, O'Donnell, G L, DeNardo, D L, Kukis, K R, Lamborn, S, Shen, A, Yuan, D S, Goldstein, C E, Carr, G R, Mirick, S J, DeNardo
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 40(12)
Encouraged by the results of 131I-Lym-1 therapy trials for patients with B-cell non-Hodgkin's lymphoma (NHL), this phase I/II clinical trial of 67Cu-2IT-BAT-Lym-1 was conducted in an effort to further improve the therapeutic index of Lym-1-based radi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::681a59435f92f26494c82a740b914cc3
https://pubmed.ncbi.nlm.nih.gov/10616879
https://pubmed.ncbi.nlm.nih.gov/10616879
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 40(12)
Accurate determination of red marrow radiation is important because myelotoxicity is often dose limiting in radioimmunotherapy. The S-value methodology assumes a fixed red marrow mass as defined by the standard Medical Internal Radiation Dose (MIRD)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb00e632b3f6603bc649273f828784d0
https://pubmed.ncbi.nlm.nih.gov/10616892
https://pubmed.ncbi.nlm.nih.gov/10616892
Autor:
R T, O'Donnell, G L, DeNardo, D L, Kukis, K R, Lamborn, S, Shen, A, Yuan, D S, Goldstein, G R, Mirick, S J, DeNardo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Copper-67 (67Cu) has ideal properties for radioimmunotherapy. The 62-h half-life is similar to the residence time of antibodies in tumor, and the therapeutic beta emission of 67Cu is comparable to that of 131I. 67Cu, however, has gamma emissions simi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f01d2b80ccf6efc56b85b00233c7c575
https://pubmed.ncbi.nlm.nih.gov/10541382
https://pubmed.ncbi.nlm.nih.gov/10541382
Autor:
G L, DeNardo, R T, O'Donnell, L A, Kroger, C M, Richman, D S, Goldstein, S, Shen, S J, DeNardo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Single-agent radioimmunotherapy (RIT) has proven efficacy as a treatment for hematological malignancies, particularly non-Hodgkin's lymphoma. Although promising, RIT has been less effective for solid tumors, in part because they are less radiosensiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::717b6eeb5b02ca3eb6157919eef1d592
https://pubmed.ncbi.nlm.nih.gov/10541367
https://pubmed.ncbi.nlm.nih.gov/10541367